Estimated frequency of events per 1000 eligible patients over lifetime among patients treated or not treated with evolocumab in addition to a statin
| Event | Untreated patients | No. of events Treated patients | Events prevented |
|---|---|---|---|
| Recurrent myocardial infarction | 460.8 | 404.9 | 56.0 |
| Cardiovascular death | 416.7 | 361.5 | 55.2 |
| New or recurrent myocardial infarction | 484.2 | 429.9 | 54.3 |
| Cardiovascular death, myocardial infarction (new or recurrent) or stroke | 752.7 | 700.7 | 51.9 |
| Stroke or transient ischemic attack | 354.2 | 324.9 | 29.3 |
| Fatal myocardial infarction | 149.2 | 120.1 | 29.2 |
| Stroke | 293.8 | 266.3 | 27.5 |
| Sudden death | 87.5 | 70.1 | 17.3 |
| Stroke death | 96.4 | 83.8 | 12.5 |
| Transient ischemic attack | 92.8 | 85.5 | 7.3 |
| Newly diagnosed diabetes | 332.5 | 327.3 | 5.2 |
| New myocardial infarction | 52.1 | 49.2 | 2.9 |
| Angina pectoris | 41.5 | 38.7 | 2.8 |
| Coronary insufficiency | 9.7 | 9.1 | 0.6 |
| Congestive heart failure death | 84.9 | 88.5 | −3.6 |
| Congestive heart failure | 107.5 | 111.2 | −3.7 |
| Other death | 579.2 | 634.6 | −55.4 |